Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Timothy Rolph Sells 1,129 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) insider Timothy Rolph sold 1,129 shares of the stock in a transaction on Wednesday, June 18th. The shares were sold at an average price of $54.84, for a total transaction of $61,914.36. Following the sale, the insider now directly owns 166,234 shares of the company's stock, valued at $9,116,272.56. The trade was a 0.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Timothy Rolph also recently made the following trade(s):

• On Tuesday, June 10th, Timothy Rolph sold 2,358 shares of Akero Therapeutics stock. The shares were sold at an average price of $54.00, for a total transaction of $127,332.00.
• On Thursday, June 5th, Timothy Rolph sold 12,500 shares of Akero Therapeutics stock. The shares were sold at an average price of $53.49, for a total value of $668,625.00.
• On Friday, June 6th, Timothy Rolph sold 25,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $55.04, for a total value of $1,376,000.00.
• On Tuesday, May 6th, Timothy Rolph sold 12,500 shares of Akero Therapeutics stock. The stock was sold at an average price of $43.43, for a total value of $542,875.00.
• On Thursday, April 24th, Timothy Rolph sold 6,250 shares of Akero Therapeutics stock. The shares were sold at an average price of $41.03, for a total value of $256,437.50.
• On Monday, April 7th, Timothy Rolph sold 6,250 shares of Akero Therapeutics stock. The stock was sold at an average price of $35.88, for a total value of $224,250.00.

Akero Therapeutics Stock Down 1.3%

Shares of AKRO stock traded down $0.70 during mid-day trading on Friday, reaching $54.20. 1,983,828 shares of the company's stock traded hands, compared to its average volume of 1,019,471. The company's 50-day moving average price is $45.88 and its 200-day moving average price is $41.10. The company has a market cap of $4.32 billion, a P/E ratio of -27.79 and a beta of -0.16. The company has a quick ratio of 16.80, a current ratio of 16.80 and a debt-to-equity ratio of 0.03. Akero Therapeutics, Inc. has a 12 month low of $21.02 and a 12 month high of $58.40.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported $0.90 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.01) by $1.91. On average, equities analysts expect that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on AKRO. Morgan Stanley reissued an "overweight" rating on shares of Akero Therapeutics in a research report on Sunday, March 2nd. Bank of America lifted their target price on shares of Akero Therapeutics from $63.00 to $64.00 and gave the company a "buy" rating in a research note on Tuesday, May 27th. HC Wainwright increased their price target on shares of Akero Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a research note on Monday, March 3rd. Finally, Citigroup lowered their price objective on shares of Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Akero Therapeutics has an average rating of "Buy" and a consensus target price of $82.50.

Hedge Funds Weigh In On Akero Therapeutics

Several large investors have recently made changes to their positions in AKRO. Tema Etfs LLC purchased a new stake in shares of Akero Therapeutics in the 4th quarter worth approximately $894,000. Cubist Systematic Strategies LLC bought a new stake in Akero Therapeutics in the fourth quarter worth $840,000. RTW Investments LP boosted its holdings in Akero Therapeutics by 15.9% in the fourth quarter. RTW Investments LP now owns 6,859,823 shares of the company's stock worth $190,840,000 after acquiring an additional 940,388 shares in the last quarter. Ameriprise Financial Inc. purchased a new stake in shares of Akero Therapeutics in the fourth quarter worth $422,000. Finally, Two Sigma Advisers LP increased its holdings in shares of Akero Therapeutics by 195.7% during the fourth quarter. Two Sigma Advisers LP now owns 41,100 shares of the company's stock valued at $1,143,000 after acquiring an additional 27,200 shares in the last quarter.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.